explore -WSS

explore

author：hotspot 2025-09-05 09:13:28 - browse：3

Illustration of doctor with an computer text bubble for a face for a story on Chat GPT and AI – health tech coverage from STAT — Mike Reddy for STAT

Health care companies are racing to incorporate generative AI tools into their product pipelines and IT systems after the technology displayed an ability to perform many tasks faster, cheaper — and sometimes better — than humans.

But the rush to harness the power of so-called large language models, which are trained on vast troves of data, is outpacing efforts to assess their value. AI experts are still trying to understand, and explain, how and why they work better than prior systems, and what blind spots might undermine their usefulness in medicine.

It remains unclear, for example, how well these models will perform, and what privacy and ethical quandaries will arise, when they’re exposed to new types of data, such as genetic sequences, CT scans, and electronic health records. Even knowing exactly how much data must be fed into a model to achieve peak performance on a given task is still largely guesswork.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Intellia reports positive results for its CRISPR

WSS

Let's speed up science by embracing open access publishing

HIV drugs protect against transmission, even in unprotected sex

Ionis drug prevents swelling attacks due to hereditary angioedema

J&J to buy cancer drug developer Ambrx Biopharma

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Intellia reports positive results for its CRISPR

focus

explore

entertainment

Apple is now the first public company to be valued at $3 trillion

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

ChatGPT in medicine: STAT answers readers' burning questions

NIH documents show early flaws of $1.6 billion long Covid program

Drug repurposing or repositioning? The language matters

Letters to First Opinion on caregivers, digital health, and more

How one medical school became remarkably diverse

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

In age of alternative facts, a scholarly course on calling out crap

Goldman Sachs launches $650M fund for life science investments

hotspot

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Let's speed up science by embracing open access publishing

White House finalizes ITC's import ban of latest Apple Watches

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

3 trends to watch in health tech's hiring outlook for 2024

NIH documents show early flaws of $1.6 billion long Covid program

knowledge

knowledge

knowledge

explore